Menu
Search
|

Menu

Close
X

Inovio Pharmaceuticals Inc INO.OQ (NASDAQ Stock Exchange Global Select Market)

4.20 USD
-- (--)
As of Feb 16
chart
Previous Close 4.20
Open --
Volume --
3m Avg Volume 291,103
Today’s High --
Today’s Low --
52 Week High 9.85
52 Week Low 3.77
Shares Outstanding (mil) 90.23
Market Capitalization (mil) 600.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
33
FY16
35
FY15
41
EPS (USD)
FY17
-0.826
FY16
-1.004
FY15
-0.440
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
11.57
5.77
Price to Book (MRQ)
vs sector
4.18
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-53.08
14.43
Return on Equity (TTM)
vs sector
-55.75
16.13

EXECUTIVE LEADERSHIP

Avtar Dhillon
Non-Executive Chairman of the Board, Since 2011
Salary: $296,314.00
Bonus: $59,535.00
Jong Kim
President, Chief Executive Officer, Director, Since 2009
Salary: $643,579.00
Bonus: $371,566.00
Peter Kies
Chief Financial Officer, Since 2002
Salary: $385,573.00
Bonus: $144,514.00
Niranjan Sardesai
Chief Operating Officer, Since 2012
Salary: $409,715.00
Bonus: $156,311.00
Mark Bagarazzi
Chief Medical Officer, Since 2010
Salary: $408,458.00
Bonus: $156,311.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10480 Wateridge Cir
SAN DIEGO   CA   92121-5773

Phone: +1858.5976006

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

SPONSORED STORIES